Polymorphisms In The Egfr Pathway As Markers For Cancer Treatment


The invention provides compositions and methods for identifying patients for single agent anti-EGFR therapy. The methods comprise determining the genomic polymorphism present in a predetermined region of a gene of interest and correlating the polymorphism to the predictive response. Patients identified as responsive are then treated with the appropriate therapy.


Sign in to the Lens